Detection Technology (DETEC) Q3 2024 earnings summary

Executive summary

• Net sales for Q3 2024 reached €27.1m, up 10.6% year-over-year, driven by strong security and industrial demand, while medical sales lagged.

• EBITA excluding non-recurring items rose to €4.2m (15.3% margin), up from €2.2m (9.0%) in Q3 2023.

• Year-to-date (Q1-Q3 2024) net sales totaled €75.9m, a 4.7% increase from the prior year, with EBITA at €9.7m and a margin of 12.8%.

• Cash flow from operating activities in Q3 was €6.4m, up from €3.3m in Q3 2023.

• Company is establishing a new service and production facility in India, with first deliveries expected in H1 2025.

Financial highlights

• Q3 EBITA (excl. NRI) was €4.2m (15.3% margin); Q1-Q3 EBITA (excl. NRI) was €9.7m (12.8% margin).

• Earnings per share in Q3 increased to €0.22 from €0.05 year-over-year.

• Net interest-bearing debt at period end was €-20.8m (net cash position).

• R&D costs represented 9.9% of Q3 net sales, down from 12.0% a year earlier.

• Investments in Q3 were €0.25m, significantly lower than €11.4m in Q3 2023.

Outlook and guidance

• Total net sales expected to remain stable year-over-year in Q4 2024 and Q1 2025.

• Security and industrial segments projected to grow in Q4, while medical is expected to decline slightly.

• Medium-term targets: annual sales growth above 10%, EBITA margin at 15%, and annual dividend or capital return of 30-60%.